Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
CADTH
Record ID 32016000122
English
Authors' recommendations:
No evidence was identified that compared the clinical effectiveness of rituximab and cyclophosphamide and/or glucocorticoids for granulomatosis with polyangiitis or microscopic polyangiitis remission maintenance after remission induction with rituximab. Adverse event evidence from four identified uncontrolled, observational trials suggested that the most common serious adverse event was infection.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.cadth.ca/sites/default/files/pdf/htis/feb-2015/RC0631%20Rituximab%20for%20GPA%20or%20MPA%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Canada
MeSH Terms
- Rituximab
- Cyclophosphamide
- Glucocorticoids
- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
- Drug-Related Side Effects and Adverse Reactions
- Infections
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.